## **GSK plc (the 'Company')** Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transaction(s): section to be repeated for (i) each type of instrumer (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary S Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.1277	8 (partnership shares)
		£16.1277	8 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	16 Ordinary Shares £16.1277	
e)	Date of the transaction	2024-04-10	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Julie Brown	
b)	Position/status	Chief Financial Officer	
c)	Initial notification/ amendment	Initial notification	
2.		er, emission allowance market participant, auction platforr tion monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.1277	7 (partnership shares)
		£16.1277	7 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	14 Ordinary Shares £16.1277	
e)	Date of the transaction	2024-04-10	
f)	Place of the transaction	London Stock Exchang	e (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio	emission allowance market participant, auction platform, n monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where en conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.12777 (partnership shares)£16.12777 (matching shares)	
d)	Aggregated information		
	Aggregated volume	14 Ordinary Shares	

	Price	£16.1277
e)	Date of the transaction	2024-04-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communic	ations and CEO Office
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	a pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.1277	8 (partnership shares)
		£16.1277	8 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	16 Ordinary Shares £16.1277	
e)	Date of the transaction	2024-04-10	
	Place of the	London Stock Exchang	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	

3.		saction; (iii) each date;	epeated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s) £16.1277 £16.1277	Volume(s) 7 (partnership shares) 7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £16.1277	
e)	Date of the transaction	2024-04-10	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply (	Chain
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti		rket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	3
3.		nsaction; (iii) each date; a	beated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63	ence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary Sh Plan	ares under the Company's Share Reward
c)	Price(s) and volume(	s) Price(s)	Volume(s)
		£16.1277	8 (partnership shares)
		£16.1277	8 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	16 Ordinary Shares £16.1277	
e)	Date of the	2024-04-10	

	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Ph	ilip Thomson	
b)	Position/status	Pr	esident, Global Affairs	
c)	Initial notification/ amendment	Init	ial notification	
2.	Details of the issuer, auctioneer or auctio			participant, auction platform,
a)	Name	GS	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			d for (i) each type of instrument; v) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Ac Pla		under the Company's Share Reward
c)	Price(s) and volume(s)	)	Price(s)	Volume(s)
			£16.1277	8 (partnership shares)
			£16.1277	8 (matching shares)
d)	Aggregated information			
	Aggregated volume Price		Ordinary Shares 6.1277	
e)	Date of the transaction	20	24-04-10	
f)	Place of the transaction	Lo	ndon Stock Exchange (XLON	)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where	

a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company Plan		ward
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.1277	8 (partnership shares)	
		£16.1277	8 (matching shares)	
d)	Aggregated information			
	Aggregated volume Price	16 Ordinary Shares £16.1277		
e)	Date of the transaction	2024-04-10		
f)	Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Victoria Whyte				
b)	Position/status	Company Secretary	Company Secretary			
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio		emission allowance market participant, auction platform, n monitor			
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D79	23			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary S Plan	hares under the Company's Share Reward			
c)	Price(s) and volume(s)	Price(s)	Volume(s)			
		£16.1277	8 (partnership shares)			
		£16.1277	8 (matching shares)			
d)	Aggregated information					
	Aggregated volume Price	16 Ordinary Shares £16.1277				
e)	Date of the transaction	2024-04-10				
f)	Place of the transaction	London Stock Exchange	(XLON)			

1.	Details of PDMR/pers	son closely associ	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Emma Walmsley					
b)	Position/status	Chief Executive Off	cer				
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, auctioneer or auctio		ce market participant, auction platform,				
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYL0	01D793				
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	dividends paid to sl	nary Shares following the re-investment of nareholders on 11 April 2024 on shares held ny's Share Reward Plan				
c)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 24				
d)	Aggregated information	N/A (single transac	tion)				
	Aggregated volume Price						
e)	Date of the transaction	2024-04-11					
f)	Place of the transaction	London Stock Excl	nange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Diana Conrad			
b)	Position/status	Chief People Officer			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			

b)	transaction	di∖	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan		
c)	Price(s) and volume(s)		Price(s) £16.3094	Volume(s) 4	
d)	Aggregated information Aggregated volume Price	N/A (single transaction)			
e)	Date of the transaction	20	24-04-11		
f)	Place of the transaction	Lo	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	James Ford			
b)	Position/status	SVP and Group Genera	Counsel, Legal and Compliance		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D7	93		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction		Shares following the re-investment of olders on 11 April 2024 on shares held Share Reward Plan		
C)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 7		
d)	Aggregated information	N/A (single transaction)			
	Aggregated volume Price				
e)	Date of the transaction	2024-04-11			
f)	Place of the transaction	London Stock Exchange	e (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	

c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio	, emission allowance market participant, auction platform, on monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO	1D793			
3.		saction; (iii) each d	be repeated for (i) each type of instrument; ate; and (iv) each place where			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan				
c)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 58			
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume Price					
e)	Date of the transaction	2024-04-11				
f)	Place of the transaction	London Stock Exch	ange (XLON)			

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Luke Miels			
b)	Position/status	Chief Commercial Officer			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auctio	uer, emission allowance market participant, auction platform, ction monitor			
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	(ii) each type of trans	etails of the transaction(s): section to be repeated for (i) each type of instrument; ) each type of transaction; (iii) each date; and (iv) each place where Insaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan			
c)	Price(s) and volume(s)	Price(s) Volume(s)			
		£16.3094 3			
d)	Aggregated	N/A (single transaction)			

-,	information	
	Aggregated volume Price	
e)	Date of the transaction	2024-04-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	David Redfern			
b)	Position/status	President Corporate	Development		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auctio		ce market participant, auction platform,		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO	1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	dividends paid to sha	ary Shares following the re-investment of areholders on 11 April 2024 on shares held ny's Share Reward Plan		
c)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 69		
d)	Aggregated information	N/A (single transact	ion)		
	Aggregated volume Price				
e)	Date of the transaction	2024-04-11			
f)	Place of the transaction	London Stock Exch	ange (XLON)		

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
h)	IFI	5493000HZTV/LIVI 01D793

0,			, ,
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63	ence each ('Ordinary Shares')
b)	Nature of the transaction		ares following the re-investment of ders on 11 April 2024 on shares held hare Reward Plan
c)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 25
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-04-11	
f)	Place of the transaction	London Stock Exchange (	(XLON)

	Details of 1 Dailype	rson closely associated w	
)	Name	Philip Thomson	
)	Position/status	President, Global Affairs	
)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction		arket participant, auction platform,
a)	Name	GSK plc	
)	LEI	5493000HZTVUYLO1D793	3
3.		nsaction; (iii) each date; a	peated for (i) each type of instrument and (iv) each place where
	u anica ca cin(c) nacio	cerr conducted	
a)	Description of the financial instrument		ence each ('Ordinary Shares')
,	Description of the	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh	nares following the re-investment of ders on 11 April 2024 on shares held
)	Description of the financial instrument Nature of the	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh dividends paid to sharehol through the Company's Sh	nares following the re-investment of ders on 11 April 2024 on shares held
))	Description of the financial instrument           Nature of the transaction	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh dividends paid to sharehol through the Company's Sh	nares following the re-investment of ders on 11 April 2024 on shares held hare Reward Plan
a) () ()	Description of the financial instrument           Nature of the transaction	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh dividends paid to sharehol through the Company's Sh s) Price(s)	nares following the re-investment of ders on 11 April 2024 on shares held hare Reward Plan Volume(s)
)) ))	Description of the financial instrument         Nature of the transaction         Price(s) and volume(s         Aggregated	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh dividends paid to sharehol through the Company's Sh s) Price(s) £16.3094	nares following the re-investment of ders on 11 April 2024 on shares held hare Reward Plan Volume(s)
))	Description of the financial instrument         Nature of the transaction         Price(s) and volume(s)         Aggregated information         Aggregated volume	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63 Acquisition of Ordinary Sh dividends paid to sharehol through the Company's Sh s) Price(s) £16.3094	nares following the re-investment of ders on 11 April 2024 on shares held hare Reward Plan Volume(s)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	93
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
	transaction(s) has be	en conducted	
a)	transaction(s) has be Description of the financial instrument		pence each ('Ordinary Shares')
a) b)	Description of the	Ordinary shares of 31 <sup>1</sup> / <sub>4</sub> ISIN: GB00BN7SWP63 Acquisition of Ordinary	y Shares following the re-investment of the second states and the second states are second states and the second states are second states and the second states are second stat
,	Description of the financial instrument Nature of the	Ordinary shares of 31 <sup>1</sup> / <sub>4</sub> ISIN: GB00BN7SWP63 Acquisition of Ordinary dividends paid to share through the Company's S	y Shares following the re-investment of the second states and the second states are second states and the second states are second states and the second states are second stat
b)	Description of the financial instrument         Nature of the transaction	Ordinary shares of 31 <sup>1</sup> / <sub>4</sub> ISIN: GB00BN7SWP63 Acquisition of Ordinary dividends paid to share through the Company's S Price(s)	y Shares following the re-investment of holders on 11 April 2024 on shares held Share Reward Plan
b)	Description of the financial instrument         Nature of the transaction         Price(s) and volume(s)         Aggregated	Ordinary shares of 31 <sup>1</sup> / <sub>4</sub> ISIN: GB00BN7SWP63 Acquisition of Ordinary dividends paid to share through the Company's S Price(s) £16.3094	y Shares following the re-investment of holders on 11 April 2024 on shares held Share Reward Plan
b)	Description of the financial instrument         Nature of the transaction         Price(s) and volume(s)         Aggregated information         Aggregated volume	Ordinary shares of 31 <sup>1</sup> / <sub>4</sub> ISIN: GB00BN7SWP63 Acquisition of Ordinary dividends paid to share through the Company's S Price(s) £16.3094	y Shares following the re-investment of holders on 11 April 2024 on shares held Share Reward Plan

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	r, emission allowance market participant, auction platform, ion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		action(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
h)	Nature of the	Acquisition of Ordinany Shares following the re-investment of

5)	transaction	dividends paid to sha	reholders on 11 April 2024 on shares l /s Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3094	Volume(s) 53	
d)	Aggregated information Aggregated volume Price	N/A (single transaction	on)	
e)	Date of the transaction	2024-04-11		
f)	Place of the transaction	London Stock Excha	nge (XLON)	

Details of PDMR/person closely associated with them ('PCA')		
Name	Dylan Jackson	
Position/status	PCA of Ms S Jackson ( Office)	SVP, Global Communications and CEO
Initial notification/ amendment	Initial notification	
		narket participant, auction platform,
Name	GSK plc	
LEI	5493000HZTVUYLO1D7	93
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
Nature of the transaction		Shares following the re-investment of olders on 11 April 2024.
Price(s) and volume(s)	Price(s)	Volume(s)
	£16.2891	24
Aggregated information	N/A (single transaction)	
Aggregated volume Price		
Date of the transaction	2024-04-11	
Place of the transaction	London Stock Exchange (XLON)	
	Name         Position/status         Initial notification/ amendment         Details of the issuer, auctioneer or auctio         Name         LEI         Details of the transaction(s) has been transaction(s) has been transaction(s) has been transaction         Nature of the transaction         Price(s) and volume(s)         Aggregated information         Aggregated volume Price         Date of the transaction         Place of the	NameDylan JacksonPosition/statusPCA of Ms S Jackson (S Office)Initial notification/ amendmentInitial notificationDetails of the issuer, emission allowance in auctioneer or auction monitorNameGSK plcLEI5493000HZTVUYLO1D7Details of the transaction(s): section to be r (ii) each type of transaction; (iii) each date; transaction(s) has been conductedDescription of the financial instrumentOrdinary shares of 31 ¼ ISIN: GB00BN7SWP63Nature of the transactionOrdinary shares of 31 ¼ ISIN: GB00BN7SWP63Nature of the transactionPrice(s) £16.2891Aggregated informationN/A (single transaction) £16.2891Aggregated volume Price2024-04-11 London Stock Exchange

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2	Datalla af tha lanu	an antiation allowance manifest neutralizant accetion whatfama

۷.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E	0793
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where sen conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ISIN: GB00BN7SWP6	¼ pence each ('Ordinary Shares') 3
b)	Nature of the transaction		<ul> <li>Shares following the re-investment of sholders on 11 April 2024</li> </ul>
c)	Price(s) and volume(s)	Price(s) £16.2891	Volume(s) 16
d)	Aggregated information Aggregated volume Price	N/A (single transaction	n)
e)	Date of the transaction	2024-04-11	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	lain Whyte	
b)	Position/status	PCA of Ms V Whyte	(Company Secretary)
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO	D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction		ry Shares following the re-investment of reholders on 11 April 2024.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2891	1090
d)	Aggregated information	N/A (single transacti	on)
	Aggregated volume Price		
e)	Date of the transaction	2024-04-11	
f)	Place of the	London Stock Excha	nge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	David Redfern		
b)	Position/status	Chief Strategy Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issue auctioneer or auct		arket participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D79	3	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction		Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA	
c)	Price(s) and volume(	s) Price(s)	Volume(s)	
		£15.3860	19	
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2024-04-12		
f)	Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
C)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, ion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

1			
b)	transaction	, ,	Shares following the re-investment of olders on 11 April 2024, on Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3860	16
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-04-12	
f)	Place of the transaction	London Stock Exchange	e (XLON)

1.	Details of PDMR/pe	rson closely associated with them ('PCA')		
a)	Name	Elizabeth McKee Ande	rson	
b)	Position/status	Independent Non-Exec	utive Director	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issue auctioneer or aucti		market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D	793	
3.	Details of the transa (ii) each type of transaction(s) has b	nsaction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where	
a)	Description of the financial instrument	American Depositary S ISIN: US37733W2044	Shares ('ADSs')	
b)	Nature of the transaction	Acquisition of ADSs fo shareholders on 11 Ap	llowing the re-investment of dividends paid to ril 2024	
c)	Price(s) and volume(s	s) Price(s) \$40.9550	Volume(s) 11	
d)	Aggregated information	N/A (single transaction	)	
	Aggregated volume Price			
e)	Date of the transaction	2024-04-12		
f)	Place of the transaction	New York Stock Exch	ange (XNYS)	

a) Nan	ame	Charles Bancroft

		I.		
b)	Position/status	Inc	lependent Non-Executi	ve Director
c)	Initial notification/ amendment	Ini	tial notification	
2.	Details of the issuer, auctioneer or auctio			arket participant, auction platform,
a)	Name	GS	SK plc	
b)	LEI	54	93000HZTVUYLO1D79	3
3.		sao	ction; (iii) each date;	epeated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument		nerican Depositary Sha N: US37733W2044	ares ('ADSs')
b)	Nature of the transaction		quisition of ADSs follo areholders on 11 April	wing the re-investment of dividends paid to 2024
c)	Price(s) and volume(s)	)	Price(s) \$40.9550	Volume(s) 68
d)	Aggregated information	N/.	A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	20	24-04-12	
f)	Place of the transaction	Ne	w York Stock Exchan	ge (XNYS)

1.	Details of PDMR/per	rson closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		inction(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where een conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024
c)	Price(s) and volume(s	Price(s)         Volume(s)           \$40.9550         13

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2024-04-12
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/pers	rson closely associated with them ('PCA')			
a)	Name	Dr	Anne Beal		
b)	Position/status	Ind	ependent Non-Executiv	e Directo	or
c)	Initial notification/ amendment	Init	ial notification		
2.	Details of the issuer, auctioneer or auctio			irket pa	rticipant, auction platform,
a)	Name	GS	SK plc		
b)	LEI	549	93000HZTVUYLO1D793	3	
3.		sac	tion; (iii) each date; a		for (i) each type of instrument; each place where
a)	Description of the financial instrument		nerican Depositary Shar N: US37733W2044	res ('ADS	Ss')
b)	Nature of the transaction		quisition of ADSs follow areholders on 11 April 2		re-investment of dividends paid to
c)	Price(s) and volume(s)	)	Price(s)		Volume(s)
			\$40.9550		9
d)	Aggregated information	N/A	A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	202	24-04-12		
f)	Place of the transaction	Ne	w York Stock Exchange	e (XNYS	;)

1.	Details of PDMR/po	erson closely associated with them ('PCA')
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, ion monitor

a)	Name	G	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.		sa	ction; (iii) each date; and	ed for (i) each type of instrument; (iv) each place where
a)	Description of the financial instrument		nerican Depositary Shares ( IN: US37733W2044	'ADSs')
b)	Nature of the transaction		equisition of ADSs following areholders on 11 April 2024	the re-investment of dividends paid to
c)	Price(s) and volume(s)	)	Price(s)	Volume(s)
			\$40.9550	9
d)	Aggregated information	N/	A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction		24-04-12	
f)	Place of the transaction	Ne	w York Stock Exchange (X	VYS)

1.	Details of PDMR/per	son closely associated with them ('PCA')	
a)	Name	Dr Jesse Goodman	
b)	Position/status	Independent Non-Execu	tive Director
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	American Depositary Sh ISIN: US37733W2044	nares ('ADSs')
b)	Nature of the transaction	Acquisition of ADSs follo shareholders on 11 Apri	owing the re-investment of dividends paid to 2024
c)	Price(s) and volume(s	Price(s) \$40.9550	Volume(s) 9
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
	Deter of the	0004.04.40	

e)	Date of the transaction	2024-04-12
f)	Place of the transaction	New York Stock Exchange (XNYS)

	Details of PDMR/per	sor	n closely associated with the	m ('PCA')
a)	Name	Dr	Vishal Sikka	
b)	Position/status	Inc	lependent Non-Executive Direc	tor
c)	Initial notification/ amendment	Init	tial notification	
2.	Details of the issuer, auctioneer or auction			articipant, auction platform,
a)	Name	GS	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.	Details of the transa (ii) each type of tran transaction(s) has be	Isac	ction; (iii) each date; and (iv	for (i) each type of instrument; each place where
a)	Description of the financial instrument		nerican Depositary Shares ('AL N: US37733W2044	DSs')
b)	Nature of the transaction	Ac sh	quisition of ADSs following the areholders on 11 April 2024	re-investment of dividends paid to
b) c)		sh	quisition of ADSs following the areholders on 11 April 2024 Price(s)	re-investment of dividends paid to Volume(s)
	transaction	sh )	areholders on 11 April 2024	
	transaction	sh	areholders on 11 April 2024 Price(s)	Volume(s)
c)	transaction Price(s) and volume(s) Aggregated	sh	areholders on 11 April 2024 Price(s) \$40.9550	Volume(s)
c)	transaction Price(s) and volume(s) Aggregated information Aggregated volume	sh )	areholders on 11 April 2024 Price(s) \$40.9550	Volume(s)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>ms@lseg.com</u> or visit <u>www.ms.com</u>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHSFSFLIELSESL